HBV

AB-506 is an orally bioavailable inhibitor of hepatitis B virus (HBV) replication that targets the viral core protein. By binding to the HBV core protein, AB-506 facilitates capsid assembly and inhibits the encapsidation of HBV pgRNA. This compound is intended for use in research related to chronic hepatitis B (CHB) and provides a valuable tool for studies on viral replication mechanisms and potential therapeutic interventions.

(S)-Canocapavir is an isomer of the antiviral agent Canocapavir, specifically targeting the HBV core protein. It functions as an HBV capsid inhibitor by binding to the hydrophobic pocket at the dimer-dimer interface of the HBV core protein (HBc). This binding promotes the intracellular accumulation of nonfunctional HBV capsids, thereby disrupting viral replication and interfering with the interaction between HBc and the HBV large surface protein. (S)-Canocapavir is relevant for research into hepatitis B virus (HBV) infection and its associated pathologies.

HBV/HDV-IN-4 hydrochloride is a dual inhibitor targeting both Hepatitis B virus (HBV) and Hepatitis D virus (HDV), demonstrating potent activity with an EC50 of less than 50 nM against HBV. This compound serves as a valuable tool for investigating therapeutic strategies in viral hepatitis research and offers potential for the development of antiviral agents against these challenging infections.

Apigenin-4'-α-L-rhamnoside is a potent inhibitor of Hepatitis B virus (HBV) primarily targeting the secretion of HBV surface antigen (HBsAg). This compound has demonstrated significant efficacy in reducing HBsAg levels in HepG2.2.15 cell lines. Its application in research facilitates the exploration of HBV pathogenesis and potential therapeutic strategies for hepatotropic viral infections.

Oleana-2,12-dien-28-oic acid is a potent HBV-DNA inhibitor that also targets HBsAg and HBeAg. This compound demonstrates significant antiviral activity, making it a valuable tool for studying hepatitis B virus infections. It is suitable for research applications focused on the mechanisms of HBV replication and potential therapeutic interventions.

(-)-Carbovir is a potent inhibitor of Hepatitis B virus (HBV) replication. It exhibits antiviral activity by specifically targeting and interfering with HBV polymerase, thereby disrupting viral nucleic acid synthesis. This compound is primarily used in research contexts focused on developing therapeutic strategies for HBV infections and understanding the mechanisms of viral resistance.

Bentysrepinine is an orally active inhibitor of the hepatitis B virus (HBV) that exhibits potent antiviral activity. It demonstrates favorable pharmacokinetic properties, with notable bioavailability across different species, including rats, dogs, and monkeys, and shows no accumulation in monkeys after 90 days of administration. This compound is being investigated for its potential applications in antiviral therapies and hepatitis research.

HBV-IN-6 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 value of 44 nM. This compound effectively interferes with viral replication, making it a valuable tool for research focused on HBV-related mechanisms and therapeutic strategies. Its efficacy underscores its potential application in developing effective treatments for HBV infections.

Antiviral Agent 38 is a potent inhibitor of the hepatitis B virus (HBV). This compound demonstrates significant antiviral activity, making it a valuable tool for research on HBV infections and their associated pathologies. Its efficacy positions it as an important reagent for studying HBV biology and potential therapeutic interventions.

HBV-IN-38 is an HBV DNA inhibitor, exhibiting an effective concentration (EC50) of ≤100 nM. This compound is primarily utilized in research to investigate the mechanisms of hepatitis B virus (HBV) infections and to evaluate potential therapeutic interventions against HBV replication.

Rolicyprine is a potent inhibitor of Hepatitis B Virus (HBV) that also exhibits neuroprotective activity. It has been shown to alleviate depressive symptoms and promote neuroregeneration, making it relevant for neuropsychiatric research. Additionally, Rolicyprine demonstrates potential in alleviating anxiety, indicating its applicability in studies related to mood disorders and HBV infections.

Erythrocentaurin is a natural compound that acts as an inhibitor of the hepatitis B virus (HBV). It exhibits potent antiviral activity, making it a promising candidate for research focused on HBV treatment and management. This compound can be utilized in studies aimed at understanding the mechanisms of HBV replication and the development of novel therapeutic strategies.

L-Fd4A is an adenine derivative that inhibits both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) with effective concentrations (EC50) of 1.5 μM and 1.7 μM, respectively. This compound demonstrates promising antiviral activity while exhibiting low cytotoxicity, making it suitable for research applications in studying HIV and HBV inhibition mechanisms.

HBV-IN-37 is a selective inhibitor of Hepatitis B virus (HBV) with an EC50 value of 10 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for researching therapeutic strategies against HBV infection. HBV-IN-37 is useful in elucidating the mechanisms of HBV replication and can serve as a lead compound in the development of antiviral agents targeting HBV.

Yhhu6669 is a potent inhibitor of Hepatitis B Virus (HBV), targeting HBV DNA replication. It functions by inducing the formation of DNA-free capsids, effectively reducing HBV levels. In preclinical studies using AAV/HBV-infected mouse models, Yhhu6669 demonstrated significant decreases in both HBV DNA and HBcAg. Additionally, it exhibits favorable pharmacokinetic properties, making it a valuable tool for research in HBV therapeutic development.

HBV-IN-7 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 of 7 nM. This compound effectively interferes with viral replication, making it a valuable tool for researching HBV pathogenesis and therapeutic interventions. Its strong antiviral activity supports applications in the development of treatments for chronic hepatitis B infections.

HBV-IN-8 is a potent inhibitor of hepatitis B virus (HBV) with an effective concentration (EC50) of 287.9 nM. This compound offers significant antiviral activity, making it a valuable tool for research applications focused on HBV infection and treatment mechanisms. HBV-IN-8 is suitable for investigations into the efficacy of antiviral agents in the pursuit of therapeutic strategies against HBV-related diseases.

GS-8873 is an orally active inhibitor targeting hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 of 4 nM. This compound demonstrates favorable pharmacokinetic properties in rat models and shows metabolic stability in human hepatocytes. While GS-8873 effectively suppresses HBV, it has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a subject of interest for further research into its biological effects and therapeutic potential.

(Rac)-AB-423 is a novel inhibitor targeting hepatitis B virus (HBV) with demonstrated antiviral activity. This compound has shown no induction of CYP1A2, CYP3A4, or CYP2B6 enzymes at elevated concentrations, indicating a favorable safety profile. Additionally, (Rac)-AB-423 exhibits advantageous pharmacokinetic characteristics, including high oral bioavailability and systemic exposure. In preclinical studies using a hydrodynamic injection HBV mouse model, (Rac)-AB-423 achieved a viral load reduction exceeding 2 log, highlighting its potential for therapeutic applications in HBV management.

HBV-IN-20 is a potent oral active inhibitor of Hepatitis B Virus (HBV), functioning primarily as a type II core protein assembly modulator (CpAM). With an EC50 of 0.46 µM, HBV-IN-20 disrupts the assembly of HBV core particles, thereby impeding viral replication. This compound is particularly valuable for research applications focused on antiviral therapy and understanding HBV biology.

AB-161 is an orally active HBV RNA destabilizer and a selective inhibitor of poly(A) polymerase domain-containing proteins 5 and 7 (PAPD5/7), primarily targeting hepatic tissues. This compound is effective in treating Hepatitis B Virus (HBV) infections by significantly reducing the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 is a valuable tool for research applications focused on understanding and addressing HBV infection.

LP10 is a non-azole inhibitor targeting CYP51, showing potent activity against Hepatitis B Virus (HBV). This compound disrupts viral replication by inhibiting 14α-demethylation, which is critical for cholesterol biosynthesis in the virus. LP10 is useful for studying HBV infection mechanisms and evaluating antiviral strategies.

DVR-01 is a hepatitis B virus (HBV) inhibitor that exhibits antiviral activity in AML12HBV10 and HepDES19 cell lines, with EC50 values of 1.7 and 1.6 μM, respectively. This compound also demonstrates efficacy against drug-resistant HBV mutants, exhibiting EC50 values ranging from 2.403 to 3.273 μM. DVR-01 is suitable for research applications focused on HBV infection and associated diseases, contributing to the understanding of viral mechanisms and potential therapeutic interventions.

KKJ00626 is a potent inhibitor of Hepatitis B virus (HBV) with an IC50 of 0.12 to 0.23 μM. This compound targets the interaction between HBV core protein and the surface protein PreS region, effectively preventing the maturation and secretion of HBV particles. Its significant antiviral activity makes KKJ00626 a valuable tool for research in HBV therapeutics and virology studies.

HBV/HDV-IN-5 is a potent inhibitor targeting hepatitis B virus (HBV) and hepatitis D virus (HDV). This compound exhibits significant antiviral activity, making it valuable for research focused on viral hepatitis. HBV/HDV-IN-5 is primarily utilized in studies exploring antiviral therapies and the mechanisms underlying HBV and HDV infections.

Morphothiadin mesylate is a potent inhibitor of Hepatitis B Virus (HBV) replication, targeting both wild-type and Adefovir-resistant strains. With an IC50 value of 12 nM, it demonstrates significant antiviral activity. This compound is useful for research applications focused on HBV pathogenesis and the development of antiviral therapeutic strategies.

Coclauril is a potent inhibitor of Hepatitis B virus (HBV) replication, acting primarily on hepatocytes. It demonstrates antiviral activity in human hepatoblastoma cell lines, with an EC50 value of 7.6 μg/mL. Coclauril is utilized in research to explore therapeutic strategies against HBV and to study the mechanisms of viral replication inhibition.

BAY39-5493 is a non-nucleoside inhibitor targeting hepatitis B virus (HBV) replication. It exerts its biological activity by blocking the formation of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.03 μM against HBV in stably transfected HepG2.2.15 cells, BAY39-5493 serves as a valuable tool for research in the field of antiviral therapeutics and HBV biology.

BAY38-7690 is a non-nucleoside inhibitor that specifically targets hepatitis B virus (HBV) replication. It functions by obstructing the assembly of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.15 μM in stably transfected HepG2.2.15 cells, BAY38-7690 is an important tool for investigating HBV biology and evaluating potential therapeutic strategies against hepatitis B virus infections.

Personalised postprandial-targeting is an HBV inhibitor that modulates water-heme interactions, specifically targeting low-spin cytochrome P450 complexes. This reagent effectively preserves the axial water ligands of CYP2C9, even when inhibitors are present, enabling advanced studies of enzyme dynamics. Additionally, it facilitates the observation of hydrogen atoms in the axial water ligands through EPR spectroscopy, offering valuable insights into the active site of the enzyme, making it a critical tool for research in enzymology and drug development.

GS-8873 TFA is a potent inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 value of 4 nM. This orally bioavailable compound demonstrates favorable pharmacokinetic properties in rodent models and metabolic stability in human hepatocytes. Notably, GS-8873 TFA has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a valuable tool for research in HBV therapies and associated neurological effects.

Telbivudine is an orally active thymidine nucleoside analog that acts as an inhibitor of hepatitis B virus (HBV) replication. Its potent antiviral activity makes it valuable in the study of HBV-related pathologies and the development of antiviral therapies. This compound serves as a significant tool for researchers investigating HBV dynamics and therapeutic interventions.

Catalpol, an iridoid glycoside derived from Rehmannia glutinosa, primarily targets hepatitis B virus (HBV) inhibition. It exhibits a broad range of biological activities including neuroprotection, hypoglycemic effects, anti-inflammatory properties, and antioxidant effects. Additionally, Catalpol demonstrates potential in anti-cancer and anti-spasmodic applications, making it valuable for various research contexts focusing on viral infections and related therapeutic interventions.